Citation | Murakami, T; Kumakura, S; Yamazaki, T; Tanaka, R; Hamatake, M; Okuma, K; Huang, W; Toma, J; Komano, J; Yanaka, M; Tanaka, Y; Yamamoto, N The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother53:2940-8 (2009) [PubMed] Article |
---|
Synonyms: | 1,1''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane} | 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane | 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O) | 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene | 11''-xylyl bis-1,4,8,11-tetraazacyclotetradecane | 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester | AMD-3100 | CHEMBL18442 | CHEMBL2311089 | PLERIXAFOR | PLERIXAFOR OCTAHYDROCHLORIDE | US9205085, MSX-162 |